Idelalisib: Targeting PI3Kδ in B-cell Malignancies
Overview
Authors
Affiliations
PI3K Targeting in Non-solid Cancer.
Kim H, Ogana H, Sanchez V, Nichols C, Kim Y Curr Top Microbiol Immunol. 2022; 436:393-407.
PMID: 36243854 PMC: 10075235. DOI: 10.1007/978-3-031-06566-8_17.
CAM-DR: Mechanisms, Roles and Clinical Application in Tumors.
Huang Y, Wang Y, Tang J, Qin S, Shen X, He S Front Cell Dev Biol. 2021; 9:698047.
PMID: 34295898 PMC: 8290360. DOI: 10.3389/fcell.2021.698047.
Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas.
Crisci S, di Francia R, Mele S, Vitale P, Ronga G, De Filippi R Front Oncol. 2019; 9:443.
PMID: 31214498 PMC: 6558009. DOI: 10.3389/fonc.2019.00443.
Targeting PI3K Signaling in Acute Lymphoblastic Leukemia.
Sanchez V, Nichols C, Kim H, Gang E, Kim Y Int J Mol Sci. 2019; 20(2).
PMID: 30669372 PMC: 6358886. DOI: 10.3390/ijms20020412.
Sun R, Yu Q, Young K Chronic Dis Transl Med. 2018; 4(1):29-44.
PMID: 29756121 PMC: 5938286. DOI: 10.1016/j.cdtm.2018.02.001.